Imperial College London
Alternate

ProfessorWaljitDhillo

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Endocrinology & Metabolism
 
 
 
//

Contact

 

+44 (0)20 7594 3487w.dhillo Website

 
 
//

Assistant

 

Ms Suzanne Wheeler +44 (0)20 7594 3487

 
//

Location

 

6N6ECommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wernig:2021:10.1016/j.mpmed.2021.06.004,
author = {Wernig, F and Jayasena, CN and Dhillo, WS},
doi = {10.1016/j.mpmed.2021.06.004},
journal = {Medicine},
pages = {544--547},
title = {Carcinoid syndrome and neuroendocrine tumours},
url = {http://dx.doi.org/10.1016/j.mpmed.2021.06.004},
volume = {49},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Neuroendocrine tumours (NETs) arise from neuroendocrine cells of the gastrointestinal tract, pancreas, bronchi or other rare primary sites and comprise a variety of different tumour types. NETs can be associated with a variety of clinical syndromes. For instance, classic symptoms of carcinoid syndrome, such as flushing and diarrhoea, occur because of the release of hormones, including serotonin, tachykinins and peptide hormones. However, most NETs are non-secretory in nature and are detected incidentally or through compression of surrounding structures. Liver metastasis has usually already occurred at the time of diagnosis. Surgery can be curative if disease is entirely localized. Injections of somatostatin analogues are the mainstay of non-surgical treatment for well-differentiated NETs. Surgical debulking and embolization techniques are useful to reduce tumour bulk in patients who remain symptomatic despite medical treatment. Peptide receptor radionucleotide therapy using radiolabelled somatostatin analogues has recently been shown to prolong progression-free survival. Furthermore, several novel agents, such as everolimus or sunitinib, have emerged in the treatment of patients with metastatic disease. This article aims to summarize the pathophysiology and clinical features of NETs, with a focus on carcinoid syndrome. It also discusses recent advances in clinical management of NETs.
AU  - Wernig,F
AU  - Jayasena,CN
AU  - Dhillo,WS
DO  - 10.1016/j.mpmed.2021.06.004
EP  - 547
PY  - 2021///
SN  - 1357-3039
SP  - 544
TI  - Carcinoid syndrome and neuroendocrine tumours
T2  - Medicine
UR  - http://dx.doi.org/10.1016/j.mpmed.2021.06.004
VL  - 49
ER  -
Download